Kaveh, Kamran Takahashi, Yutaka Farrar, Michael A. Storme, Guy Guido, Marcucci Piepenburg, Jamie Penning, Jackson Foo, Jasmine Leder, Kevin Z. K. Hui, Susanta Radiation and Nilotinib dose responses. <p>a) Radiation dose-response curve under no Nilotinib treatment (magenta) and 18 nM Nilotinib (red). Solid lines are model predictions with independently fitted parameters (from Tables <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1005482#pcbi.1005482.t001" target="_blank">1</a> and <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1005482#pcbi.1005482.t002" target="_blank">2</a>). Experimental data shown in circles. Cell viabilities are measured after three days. b) Nilotinib dose-response curves in absence of radiation. Solid lines are model predictions with independently fitted parameters, experimental data shown in circles. Cell viabilities are measured after three days. Other lines represent model predictions for efficacy of Nilotinib treatment combined with various radiation doses of 1, 2, 3 and 4 Gy.</p> drug-resistance Philadelphia chromosome-positive;Nilotinib;LDR;TKI;Decreased expression level;combination therapy;cell viability experiments;tyrosine kinase inhibitor;AKT;lymphoblastic leukemia;model 2017-07-06
    https://plos.figshare.com/articles/figure/Radiation_and_Nilotinib_dose_responses_/5179150
10.1371/journal.pcbi.1005482.g006